INVIVYD, INC.

IVVD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023
Revenue $53.4M $25.4M $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $38.3M $137.3M $158.7M
SG&A Expense $66.9M $63.4M $49.1M
Operating Income $-55.6M $-176.9M $-212.8M
Operating Margin -104.0% -696.8%
Interest Expense
Pretax Income
Income Tax Expense $0 $0 $0
Net Income $-52.5M $-169.9M $-198.6M
Net Margin -98.2% -669.4%
EPS (Basic) $-0.30 $-1.43 $-1.81
EPS (Diluted) $-0.30 $-1.43 $-1.81
Shares Outstanding (Basic) 172.2M 118.6M 109.5M
Shares Outstanding (Diluted) 172.2M 118.6M 109.5M
Dividends Per Share